Summary
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
History
Denali Therapeutics was founded in 2015 by world-renowned scientists and biotech leaders with a shared vision of reversing the course of devastating diseases by creating transformative medicines. The company combines scientific, medical and drug development expertise with a deep understanding of the genetic and molecular causes of disease, enabling the development of precision medicines designed to treat the underlying causes of neurologic disorders.
Mission
Our mission is to discover and develop breakthrough medicines to extend and improve the lives of people with neurological diseases and to be a leader in advancing precision medicine.
Vision
Our vision is to convert revolutionary discoveries into innovative and transformative therapies that change the lives of people with certain neurological disorders, especially Alzheimer’s disease and Parkinson’s disease.
Key Team
Mr. Steve Edward Krognes (Treasurer & Director)
Dr. Carole Ho M.D. (Chief Medical Officer & Head of Devel.)
Mr. Tyler M. Nielsen (Sr. VP of Corp. Fin.)
Dr. Dana Andersen (Chief Technical and Manufacturing Officer)
Mr. Joe Lewcock (Chief Scientific Officer)
Dr. Laura Hansen (VP of Investor Relations)
Mr. Chris Walsh (Gen. Counsel)
Recognition and Awards
Denali has been recognized for its commitment to excellence and innovation with several awards, including the 2020 Prix Galien USA award for Innovative Product FoU6.
References
United States 
